New Market - May 19, 2017
Sobi’s Elocta approved in Saudi Arabia
Swedish Orphan Biovitrum announces that the Saudi Food & Drug Authority (SFDA) in the Kingdom of Saudi Arabia has approved Elocta (efmoroctocog alfa), a recombinant human factor VIII Fc-fusion protein with an extended half-life, for the treatment of haemophilia A. Elocta is the first extended half-life and recombinant factor VIII Fc fusion protein therapy approved […]
Pharma Business - March 29, 2016
Transfer of marketing authorisation for Elocta to Sobi approved
The European Commission has approved the transfer of the marketing authorisation for Elocta® (efmoroctocog alfa) from Biogen to Sobi, making Sobi the marketing authorisation holder of Elocta in the EU. Elocta is a recombinant human factor VIII Fc fusion protein with an extended half-life and is the first haemophilia A treatment in the EU to […]
Pharma Business - January 12, 2016
Sobi launches Elocta in first countries in Europe
Swedish Orphan Biovitrum AB has announced the commercial launch of Elocta (efmoroctocog alfa) in first countries in Europe. Elocta is a recombinant human factor VIII Fc fusion protein with an extended half-life, and is the first haemophilia A treatment in the EU to offer prolonged protection against bleeding episodes with prophylactic injections every three to […]
Companies - April 15, 2015
Elocta Gets Orphan Status
Swedish Orphan Biovitrum AB has received orphan drug designation in Switzerland for its long acting hemophilia drug candidate Elocta (rFVIIIFc), developed for the treatment of hemophilia A. An orphan drug designation encourages the development of medicines for rare diseases and provides orphan status to drugs and biologics under development. Elocta is a long-acting recombinant factor […]
